Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y587
UPID:
AP4S1_HUMAN
Alternative names:
AP-4 adaptor complex subunit sigma-1; Adaptor-related protein complex 4 subunit sigma-1; Sigma-1 subunit of AP-4; Sigma-4-adaptin
Alternative UPACC:
Q9Y587; G3V2N8; Q6IAQ4; Q86U36; Q9BVE7
Background:
AP-4 complex subunit sigma-1, also known as Adaptor-related protein complex 4 subunit sigma-1, plays a crucial role in vesicular transport processes. It is a component of the adaptor protein complex 4 (AP-4), which is involved in forming vesicle coats not associated with clathrin, facilitating the transport of proteins from the trans-Golgi network to the endosomal-lysosomal system. This protein is essential for the sorting of proteins to the basolateral membrane in epithelial cells and for the asymmetric localization of somatodendritic proteins in neurons.
Therapeutic significance:
AP-4 complex subunit sigma-1's involvement in Spastic paraplegia 52, a neurodegenerative disorder, highlights its potential as a target for therapeutic intervention. Understanding the role of AP-4 complex subunit sigma-1 could open doors to potential therapeutic strategies for treating this debilitating condition.